SCHEMBL3989391

SCHEMBL3989391

COc1ccc(-c2cc3c(cc2NC(C)=O)Cc2sc(N)nc2-3)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 13/20 0.61
MAPT P10636 6/20 0.56
ALDH1A1 P00352 5/20 0.56
TDP2 O95551 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
NPC1 O15118 2/20 0.56
RAB9A P51151 2/20 0.56
HSD17B10 Q99714 1/20 0.56
KDM4E B2RXH2 3/20 0.51
MPI P34949 1/20 0.51
MEN1 O00255 2/20 0.48
APAF1 O14727 2/20 0.48
KMT2A Q03164 2/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
CASP3 P42574 1/20 0.48
BLM P54132 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL3986093 0.99 ADORA1 (0.62) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
Iodide SCHEMBL3994525 0.89 ADORA1 (0.49) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
Iodide SCHEMBL3989389 0.87 ADORA1 (0.65) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
SCHEMBL13944121 0.86 MAPT (0.62) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
SCHEMBL13944123 0.86 ADORA1 (0.61) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
SCHEMBL13944118 0.82 ADORA1 (0.45) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
Iodide SCHEMBL3994386 0.81 ADORA1 (0.47) ADORA1ALDH1A1FBP1GAA
Iodide SCHEMBL3992012 0.78 ADORA1 (0.52) ADORA1MAPTALDH1A1TDP2SMN1; SMN2
Iodide SCHEMBL3989097 0.78 ADORA1 (0.66) ADORA1ALDH1A1SMN1; SMN2FBP1GAA
Iodide SCHEMBL3993066 0.76 ADORA1 (1.00) ADORA1MAPTALDH1A1KDM4EMPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485655-B2 2-Aminothiazole allosteric enhancers of A1 adenosine receptors UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2009-02-03 US disclosed
US-20050027125-A1 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027125-A1 2-Aminothiazole allosteric enhancers of a ?1? adenosine receptors ADORA1, ADORA2A, ADORA2B ADORA1 1/4885MAPT 3615/4885ALDH1A1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.